Gefticip 250 mg Tablet
$19.82
$10.40
Gefticip 250 mg Tablet is an effective medication designed for the treatment of advanced non-small cell lung cancer (NSCLC) in adults whose cancer has progressed due to mutations in the EGFR gene and who have not received prior treatment. This targeted therapy works by inhibiting the growth of cancer cells, thereby helping to slow disease progression and improve patient outcomes. It is essential to note that Gefticip is not recommended for children or adolescents, as its safety and efficacy in these populations have not been established. Patients should also be aware of potential side effects, which may include gastrointestinal issues and skin reactions, and should consult their healthcare provider for monitoring throughout their treatment. When using Gefticip, it is crucial to adhere to the prescribed dosage and discuss any other medications being taken to avoid harmful interactions. This innovative drug represents a significant advancement in cancer therapy, offering hope for those battling this challenging condition. Always seek guidance from a healthcare professional to ensure that Gefticip is the right choice for your treatment plan.
मात्रा
Active Pharmaceutical Ingredient
Uses
• Gefticip 250 mg tablet is primarily indicated for the treatment of non-small cell lung cancer (NSCLC). This type of lung cancer is characterized by the presence of abnormal cells that can rapidly proliferate. By targeting specific pathways involved in tumor growth, Gefticip 250 mg tablet helps to slow down the progression of the disease. It is often utilized in patients who have advanced or metastatic forms of NSCLC.
• Patients diagnosed with non-small cell lung cancer may benefit from Gefticip 250 mg tablet as part of their treatment regimen. The medication works by inhibiting certain proteins that contribute to cancer cell survival and proliferation. In this way, Gefticip 250 mg tablet assists in managing the symptoms and overall impact of the disease. It is particularly useful for those who have not responded well to other therapies.
• Gefticip 250 mg tablet is also used in combination with other cancer treatments to enhance therapeutic effectiveness. This combination approach can be beneficial for patients with varying stages of non-small cell lung cancer. By integrating Gefticip 250 mg tablet into their treatment plan, healthcare providers aim to improve patient outcomes. It helps in reducing tumor burden and improving quality of life.
• The use of Gefticip 250 mg tablet is guided by the specific needs of each patient with non-small cell lung cancer. Oncologists may recommend this medication based on the cancer's characteristics and the patient's overall health status. Gefticip 250 mg tablet can be an important part of a personalized treatment strategy. Its targeted action plays a crucial role in managing this challenging disease.
Benefits
Gefitinib 250 mg Tablet inhibits a protein called epidermal growth factor receptor (EGFR), which is involved in the growth and spread of cancer cells. By inhibiting this protein, Gefticip Lung Cancer Tablet may help to slow the progression of cancer.
Gefticip 250 mg may help reduce the severity of cancer-related symptoms, such as pain and fatigue, which can improve a patient's overall quality of life.
Gefitinib 250 mg Tablet may be used in combination with other cancer treatments, such as chemotherapy, to improve their effectiveness.
Side Effects
As with all medicines, Gefticip 250 mg Cipla Tablet may cause some side effects. If you experience any of these side effects, you should contact your doctor or health care professional as soon as possible. Your doctor may be able to suggest ways in which these side effects can be managed or the severity of them reduced.
Most Common Side Effects
• Tremor
• Hypertension
• Headache
• Increased Potassium levels in the blood
• Hypertension
• Gastrointestinal problems
• Abnormal Growth of Hair
Common Side Effects
• Liver Damage
• Seizures
• Infection
• Kidney Damage
• Memory Problems
• Vision Problems
• Sleeplessness
How To Use
It is recommended to consume Gefticip 250 mg Cipla Tablet with or without food. Be sure to swallow the tablet whole with a complete glass of water. Avoid crushing, chewing, or opening the tablet. In case you forget to take a dose, take it as soon as you remember. However, if it is nearly time for your next dose, skip the missed dose and adhere to your regular dosing schedule. Remember not to take two doses simultaneously to compensate for a missed dose.
Safety Advice
• Alcohol: The use of alcohol is generally not recommended while taking Anti-cancer Drug Gefticip as it may increase the risk of liver damage. It is advisable to either abstain from alcohol or limit your alcohol intake while taking any medication.
• Kidney: Gefticip 250 mg Tablet is considered safe for patients with mild to moderate kidney disease and no dose adjustment of Gefticip 250 mg is required. However, people with severe kidney disease are advised not to take Gefticip Lung Cancer Tablet Tablet. To ensure the safety and effectiveness of your treatment, it is important to have an open discussion with your doctor about all your medical conditions and medications.
• Breastfeeding: It is not advisable to breast-feed while taking Gefticip Lung Cancer Tablet as this may cause harm to the baby. Gefticip 250 mg Tablet can pass into breast milk and cause adverse effects. If you are currently breastfeeding and using Gefitinib 250 mg Tablet, it is important to discuss with your doctor the potential risks and benefits of continuing to breastfeed. Your doctor will help you make the decision that is best for you and your baby.
• Liver: Gefticip 250 mg Tablet is considered safe for patients with mild to moderate liver disease, and there is no need to adjust the dose of Gefitinib 250 mg Tablet. However, people with severe liver disease should not use Anti-cancer Drug Gefticip. It is important to have an open discussion with your doctor about your medical conditions and medications to ensure that the treatment plan is appropriate for you.
• Pregnancy: Gefticip 250 mg Tablet may be unsafe during pregnancy as animal studies suggest that it may harm the developing fetus. However, if you are pregnant or planning to get pregnant, it is important to talk to your doctor about the potential risks and benefits of taking Gefticip 250 mg Cipla Tablet while pregnant. Your doctor will be able to help you make the decision that is best for you and for the health of your baby.
• Driving: Gefticip 250 mg Tablet may cause dizziness, drowsiness, and problems with concentration and coordination, which may impair your ability to drive a vehicle safely. It is important that you follow your doctor's instructions and take the necessary measures, such as avoiding driving or operating heavy machinery, if you experience any of these side effects caused by Gefitinib 250 mg Tablet.